Jyoti S. Mayadev, MD, Compares Efficacy of Durvalumab/CRT Vs Placebo/CRT in High-Risk Locally Advanced Cervical Cancer

Video

The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.

At the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Jyoti S. Mayadev, MD, a radiation oncologist and professor of radiation medicine and applied sciences at the University of California San Diego School of Medicine, spoke with CancerNetwork® about key findings from the phase 3 CALLA trial (NCT03830866), assessing the addition of durvalumab (Infinzi) to chemoradiotherapy (CRT) vs placebo/CRT in patients with high-risk locally advanced cervical cancer.

The 12-month progression-free survival (PFS) rate was 76.0% for patients receiving durvalumab with CRT and 73.3% for those in the placebo arm. Additionally, the 24-month PFS rate was 65.9% in the durvalumab arm and 62.1% for those receiving placebo (HR, 0.84; 95% CI, 0.65-1.08; P = .174). Mayadev also discussed the trial’s international design and her takeaway from the subgroup analysis.

Transcript:

This was a global effort. We had more than 120 sites [in] 15 countries across the globe [and enrolled] patients with high-risk cervical cancer; these were truly high-risk patients. More than two-thirds had node-positive disease, and [had] stage IIIA/IVA disease. We randomized 770 patients in less than 2 years during a pandemic to CRT [and] durvalumab vs. placebo. Our primary objective was progression-free survival [PFS]. At 1 year, the PFS was no different between the durvalumab arm and the placebo arm. In terms of the hazard ratios in more granular detail, the 12-month PFS rate with the durvalumab/chemoradiation [arm] was 76.0% vs 73.3% with a placebo arm. At 24 months, the rate in durvalumab arm was 65.9% vs 62.1% with placebo. The hazard ratio was 0.84 and the P value was 0.174. We’ve presented the maturity at 31% at ASTRO 2022 as a plenary session. The median follow-up time was 18.5 months. In terms of the subgroup analysis, depending on the nodal status or the timeliness of radiation, there were no differences in terms of the durvalumab arm [vs the placebo arm].

Reference

Mayadev JS, Rong, Y, Toita T, et al. Durvalumab in combination with chemoradiotherapy (CRT) in locally advanced cervical cancer (LACC): radiotherapy (RT) delivery and subgroup analyses from CALLA. Presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting; October 23-26, 2022; San Antonio, TX; LBA 03. Accessed October 27, 2022.

Related Videos
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Related Content